WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 712

Legislative bill overview

HB 712 mandates that health benefit plans in Texas cover certain prostate cancer screening tests without cost-sharing requirements (copays, coinsurance, or deductibles). The bill applies to diagnostic tests used to detect prostate cancer in individuals who may be at risk or showing symptoms.

Why is this important

Prostate cancer is the most commonly diagnosed cancer in Texas men. By removing financial barriers to screening tests, the bill aims to increase early detection rates, which generally improves treatment outcomes and reduces long-term healthcare costs. This directly affects insurance coverage requirements for Texas residents and insurers operating in the state.

Potential points of contention

  • Medical guideline conflicts: Major organizations (AMA, USPSTF) recommend individualized screening discussions rather than universal coverage, citing concerns about overdiagnosis and overtreatment of slow-growing cancers
  • Insurance cost implications: Removing cost-sharing increases premiums across plans, potentially raising healthcare costs for all enrollees to benefit a subset of the population
  • Test specificity undefined: The bill's language regarding "certain tests" may be ambiguous—unclear whether it covers PSA blood tests, digital rectal exams, or emerging biomarker tests, creating implementation challenges

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.